NDAOPHTHALMICSOLUTION/DROPS
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
4/8 — Partial
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RHOPRESSA (netarsudil) is a small-molecule ophthalmic solution approved in 2017 for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is a Rho kinase inhibitor that works by increasing conventional outflow of aqueous humor and decreasing episcleral venous pressure. The drug represents a novel mechanism of action in the glaucoma treatment armamentarium.
$0.175BPart D
Peak7.7 years to LOEProduct is at peak commercial stage with $175M in annual Part D spending, indicating a mature, stable commercial organization focused on market penetration rather than rapid scaling.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension
Started Jun 2026
50 enrolled
GlaucomaOcular Hypertension
Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT
Started Jun 2025
70 enrolled
Primary Open Angle Glaucoma or Ocular Hypertension
Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
Started Aug 2024
Why This Matters for Your Career
Worked on RHOPRESSA at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.